These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1111876)

  • 1. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy.
    Silverberg DS; Bettcher KB; Dossetor JB; Overton TR; Holick MF; DeLuca HF
    Can Med Assoc J; 1975 Jan; 112(2):190, 193-5. PubMed ID: 1111876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
    Moorthy AV; Harrington AR; Mazess RB; Simpson DP
    Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol.
    Velentzas C; Oreopoulos DG; Pierratos A; Meema HE; Rabinovich S; Meindok H; Husdan H; Murray TM; Ogilvie R; Katirtzoglou A
    Can Med Assoc J; 1981 Mar; 124(5):577-83. PubMed ID: 6894103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
    Coburn JW; Brickman AS
    Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
    Reutter FW; Sieber R; Olah AJ; Dambacher MA
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings: Bone demineralization in renal failure: a longitudinal study of the distal femur using photon absorptiometry.
    Overton TR; Silverberg DS
    AJR Am J Roentgenol; 1976 Jun; 126(6):1289-91. PubMed ID: 179410
    [No Abstract]   [Full Text] [Related]  

  • 10. 1,25-Dihydroxycholecalciferol in dialysed patients with clinically asymptomatic renal osteodystrophy. A controlled study.
    Fischer JA; Binswanger U
    Contrib Nephrol; 1980; 18():82-91. PubMed ID: 7353381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of whole body and regional assessments of calcium balance in renal osteodystrophy in the response to 1 alpha-hydroxy vitamin D3.
    Naik RB; Robertson PW; Robinson BH; Dabek JT; James HM; Kanis JA
    Proc Eur Dial Transplant Assoc; 1977; 14():425-32. PubMed ID: 600960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.
    Chan JC; Lovinger RD; Mamunes P
    Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
    Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
    Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence that different vitamin D sterols have qualitatively different effects in man.
    Rasmussen H; Bordier P
    Contrib Nephrol; 1980; 18():184-91. PubMed ID: 7353375
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
    Chesney RW; Hamstra A; Jax DK; Mazess RB; DeLuca HF
    Contrib Nephrol; 1980; 18():55-71. PubMed ID: 7353380
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.